Loading...
Loading...
TLIS| Name | Value |
|---|---|
| Revenues | 0.1M |
| Cost of Revenue | 2.3M |
| Gross Profit | -2.2M |
| Operating Expense | 25.9M |
| Operating I/L | -28.1M |
| Other Income/Expense | 1.2M |
| Interest Income | 0.0M |
| Pretax | -26.9M |
| Income Tax Expense | -61.4M |
| Net Income/Loss | 34.5M |
Talis Biomedical Corporation is a molecular diagnostic company that is focused on developing the Talis One system to improve point-of-care diagnostic testing for infectious diseases. The company's primary revenue comes from the Talis One COVID-19 Test System, designed for the detection of SARS-CoV-2, the virus responsible for COVID-19. Additionally, it offers assay kits for respiratory infections, women's health-related infections, and sexually transmitted infections. The company also provides tests for other respiratory infections, including a respiratory panel test for influenza A, influenza B, and respiratory syncytial virus.
